Axsome Therapeutics (AXSM) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
385.7M
Gross Profit
352.4M
91.37%
Operating Income
-252.4M
-65.45%
Net Income
-287.2M
-74.47%
EPS (Diluted)
-$5.99
Balance Sheet Metrics
Total Assets
568.5M
Total Liabilities
511.5M
Shareholders Equity
57.0M
Debt to Equity
8.97
Cash Flow Metrics
Operating Cash Flow
-180.6M
Free Cash Flow
-128.7M
Revenue & Profitability Trend
Axsome Therapeutics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 385.7M | 270.6M | 50.0M | 0 | 0 |
| Cost of Goods Sold | 33.3M | 26.1M | 5.2M | 0 | 0 |
| Gross Profit | 352.4M | 244.5M | 44.8M | 0 | 0 |
| Operating Expenses | 598.4M | 421.1M | 217.2M | 124.7M | 99.1M |
| Operating Income | -252.4M | -182.9M | -176.5M | -124.7M | -99.1M |
| Pre-tax Income | -287.1M | -238.3M | -187.1M | -130.4M | -102.9M |
| Income Tax | 85.0K | 960.0K | 0 | 0 | - |
| Net Income | -287.2M | -239.2M | -187.1M | -130.4M | -102.9M |
| EPS (Diluted) | -$5.99 | -$5.27 | -$4.60 | -$3.47 | -$2.77 |
Income Statement Trend
Axsome Therapeutics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 485.1M | 504.3M | 245.6M | 86.5M | 184.0M |
| Non-Current Assets | 83.4M | 84.0M | 85.8M | 1.3M | 2.1M |
| Total Assets | 568.5M | 588.2M | 331.5M | 87.8M | 186.1M |
| Liabilities | |||||
| Current Liabilities | 230.1M | 138.9M | 96.6M | 23.1M | 23.4M |
| Non-Current Liabilities | 281.4M | 258.4M | 125.4M | 49.1M | 48.9M |
| Total Liabilities | 511.5M | 397.3M | 221.9M | 72.2M | 72.3M |
| Equity | |||||
| Total Shareholders Equity | 57.0M | 191.0M | 109.6M | 15.6M | 113.8M |
Balance Sheet Composition
Axsome Therapeutics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -287.2M | -239.2M | -187.1M | -130.4M | -102.9M |
| Operating Cash Flow | -180.6M | -176.2M | -157.7M | -108.9M | -78.1M |
| Investing Activities | |||||
| Capital Expenditures | -270.0K | -582.0K | -702.0K | -308.0K | -45.9K |
| Investing Cash Flow | -270.0K | -582.0K | -53.7M | -308.0K | -45.9K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 27.2M | 318.6M | 278.3M | 6.7M | 41.4M |
| Free Cash Flow | -128.7M | -145.7M | -117.2M | -108.5M | -78.5M |
Cash Flow Trend
Axsome Therapeutics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-16.97
Forward P/E
-47.06
Price to Book
94.03
Price to Sales
11.58
PEG Ratio
-47.06
Profitability Ratios
Profit Margin
-64.39%
Operating Margin
-45.67%
Return on Equity
-282.16%
Return on Assets
-26.17%
Financial Health
Current Ratio
2.03
Debt to Equity
397.02
Beta
0.47
Per Share Data
EPS (TTM)
-$5.77
Book Value per Share
$1.08
Revenue per Share
$8.95
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| axsm | 5.0B | -16.97 | 94.03 | -282.16% | -64.39% | 397.02 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.